MetaCap

Arcturus Therapeutics (ARCT) vs Faeth Therapeutics (FTH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arcturus Therapeutics (ARCT) has outperformed Faeth Therapeutics (FTH) over the past year, gaining 19.0% versus a loss of 9.6%. Over five years, ARCT leads with a -81.3% price change compared with -95.0% for FTH. Arcturus Therapeutics is the larger company by market cap ($214.7 million vs $203.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARCT+19.01%FTH-9.64%
+378%+174%-30%
Nov 21, 20251 yearNov 20, 2026
ARCT-79.56%FTH-95.34%
+35%-34%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARCT versus FTH key metrics
MetricARCTFTH
Share price$7.45$7.88
Market cap$214.73M$203.65M
1-day change-1.97%-9.32%
YTD return+21.53%-26.15%
1-year return+19.01%-9.64%
5-year return-81.32%-94.96%
EPS (TTM)$-3.10$-22.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$82.03M—
Revenue growth (YoY)-46.14%—
Net income (latest FY)$-65.78M$-21.09M
Operating margin-92.96%—
Net margin-80.19%—
52-week high$17.96$42.14
52-week low$5.50$7.45
Distance from 52-week high-58.52%-81.30%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+218.12%+612.56%
Average volume851.45K500.25K
Shares outstanding28.82M25.84M
Employees10629
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARCT has outperformed FTH by 28.7 percentage points over the past year.

About Arcturus Therapeutics

ARCT stock →

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

About Faeth Therapeutics

FTH stock →

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

ARCT vs FTH FAQ

Which is bigger, Arcturus Therapeutics or Faeth Therapeutics?

Arcturus Therapeutics (ARCT) is larger, with a market capitalization of $214.73M compared with $203.65M for Faeth Therapeutics (FTH).

Which stock has performed better over the past year, ARCT or FTH?

ARCT returned +19.01% over the past 12 months, compared with -9.64% for FTH (price return, excluding dividends). Past performance does not predict future results.

Are Arcturus Therapeutics and Faeth Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons